Sign in

Bing Zhao

Research Analyst at China Renaissance

Bing Zhao is an Equity Research Analyst at China Renaissance Securities, specializing in healthcare sector coverage with a particular focus on biopharmaceutical and life sciences companies. He has covered companies including I-Mab and BeOne Medicines, providing detailed research and engaging directly with management through earnings call participation. Bing Zhao began his analyst career at China Renaissance in the late 2010s and has contributed to research recognized by institutional clients, but publicly available performance rankings or quantitative track records are limited. While Bing Zhao is listed as a covering analyst by multiple companies, there is no public record of FINRA registration or specific professional securities licenses.

Bing Zhao's questions to NovaBridge Biosciences (IMAB) leadership

Question · H1 2023

Bing Zhao asked how the potential approval of Astellas' zolbetuximab might impact the clinical plan for givastomig and questioned the rationale for selecting a 4-1BB bispecific target over others.

Answer

CMO John Hayslip and President Andrew Zhu highlighted givastomig's differentiation, citing its efficacy across a broad range of Claudin expression levels and a more favorable safety profile with less GI toxicity than competing monoclonal antibodies. This positions it strongly for the first-line setting. The 4-1BB target was chosen for its ability to conditionally activate the immune system within the tumor microenvironment, thereby minimizing systemic side effects.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts